Poster presentation demonstrating combination benefit of narmafotinib in preclinical kRAS-mutated cancer models

Compelling data describing new clinical opportunities for Amplia’s lead drug narmafotinib was presented at the AACR Special Conference in Cancer Research: RAS Oncogenesis and Therapeutics in Los Angeles, California last week.  

The poster presentation discloses preclinical data demonstrating that the Company’s best-in-class FAK inhibitor narmafotinib enhances the activity of kRAS inhibitors – an exciting new class of drugs - in various models of cancer. In particular, the data indicates that narmafotinib blocks resistance pathways that can emerge with kRAS inhibitor treatment, thereby enhancing efficacy and durability of response. 

Amplia CEO Dr Chris Burns commented,  

"We are excited to present our research findings at this specialist conference focused on RAS inhibition in cancer. We believe there is significant clinical potential in combining narmafotinib with kRAS inhibitors and will be discussing our findings with pharma and biotech companies actively working in this space." 

Click to read the ASX release.